Trametinib

Trametinib has been studied in 22 papers since 2016: none in people yet, 15 in animals, 3 in cells, 3 reviews; 6 in the past year. The research so far is in animals and cells. The newest story, Oct 29, 2026: “Drug combination limited brain tumor regrowth in mice”.

InterventionApproved 2014

22 papers study it5 more mention it25 findingsUpdated

PubChemChEBIMeSH

1 new paper in 30 daysSee all 27 papers on trametinib

At a glance

The findings reach mice, none yet in people; independent labs found the same change in cells and worms or flies. 10 independent labs in 5 countries; 206 trials, none about aging, 50 with no results posted.

3 of its findings point the other way.

Cells and worms or flies: replicated by independent labs. Mice: a single group. Humans: nothing yet.
  • 10 independent labs in 5 countries
  • 3 findings against
  • 206 trials, none about aging, 50 with no results posted
  • Funders: National Institutes of Health and others
  • 5 of 26 findings with company ties
  • 37 of 206 trials sponsored by its developers
  • Animals6
  • Model organisms9
  • Cells3
  • In silico1

What did lifespan studies of trametinib find?

DrugAge

DrugAge records 1 result from 1 paper: 1 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of trametinib find?

18

Studies of trametinib measured 18 outcomes; the most studied are lifespan (4 studies) and cellular senescence (3).

Lifespan

upin flies3upin mice1

4 studies
  1. Trametinib extends lifespan in mice.

    “trametinib treatment extended lifespan in both sexes”

    Animalsmale and females

    The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan

    Nature aging

  2. Trametinib extends lifespan in flies.

    “trametinib consistently and robustly extends female lifespan”

    Model organismsfemales

    Trametinib ameliorates aging-associated gut pathology in Drosophila females by reducing Pol III activity in intestinal stem cells

    Proceedings of the National Academy of Sciences of the United States of America

  3. Trametinib extends lifespan in TDP-43 flies.

    “prolonged the lifespan of TDP-43 flies”

    Model organismsin TDP-43 flies

    Inhibition of the MEK/ERK pathway suppresses immune overactivation and mitigates TDP-43 toxicity in a Drosophila model of ALS

    Immunity & ageing : I & A

  4. Trametinib extends lifespan in flies.

    “we identify Ras inhibition as an effective lifespan-extending manipulation in males as well as females”

    Model organisms

    Ras inhibition by trametinib treatment in Drosophila attenuates gut pathology in females and extends lifespan in both sexes

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

Cellular senescence

downin human cells2no changein human cells1upin mice1

3 studies
  1. Trametinib induces cellular senescence in mice (pediatric BRAF-V600E glioma).

    “Trametinib induced a robust senescent phenotype in BT-40 tumours in vivo”

    Animalspediatric BRAF-V600E gliomaBT-40 tumor

    Drug combination limited brain tumor regrowth in mice

    Neuro-oncology

  2. Trametinib inhibits cellular senescence in DKFZ-BT66 cells.

    “Trametinib treatment inhibited MAPK activity, OIS and SASP signatures across all omics levels, functionally underscored by reduced sensitivity towards senolytic drugs.”

    Cellsin DKFZ-BT66 cells

    Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

    Signal transduction and targeted therapy

  3. Trametinib showed no clear effect on cellular senescence in Werner syndrome cells.

    “Werner syndrome cells did not demonstrate changes in in senescence following treatment.”

    Cellsin Werner syndrome cells

    Senescence, regulators of alternative splicing and effects of trametinib treatment in progeroid syndromes

    GeroScience

  4. Trametinib decreases cellular senescence in HGPS and Cockayne syndromes.

    “10 μM trametinib reduced senescent cell load and affected other aspects of the senescence phenotype (including splicing factor expression) in HGPS and Cockayne syndromes.”

    Cellsin HGPS and Cockayne syndromes10 μM

    Senescence, regulators of alternative splicing and effects of trametinib treatment in progeroid syndromes

    GeroScience

More on Cellular senescence

Survival

upin flies1

1 study
  1. Trametinib increases survival in flies (high-sugar diet).

    “trametinib, mitigates several of the detrimental effects of a high-sugar diet by reducing TAG accumulation, restoring TAG composition, and increasing survival.”

    Model organismshigh-sugar diet

    Pharmacological protection from a sugar-rich diet through inhibition of Ras/MAPK signaling

    iScience

Triacylglyceride composition

upin flies1

1 study
  1. Trametinib improves triacylglyceride composition in flies (high-sugar diet).

    “trametinib, mitigates several of the detrimental effects of a high-sugar diet by reducing TAG accumulation, restoring TAG composition, and increasing survival.”

    Model organismshigh-sugar diet

    Pharmacological protection from a sugar-rich diet through inhibition of Ras/MAPK signaling

    iScience

More on Triacylglyceride composition

Triacylglyceride accumulation

downin flies1

1 study
  1. Trametinib decreases triacylglyceride accumulation in flies (high-sugar diet).

    “trametinib, mitigates several of the detrimental effects of a high-sugar diet by reducing TAG accumulation, restoring TAG composition, and increasing survival.”

    Model organismshigh-sugar diet

    Pharmacological protection from a sugar-rich diet through inhibition of Ras/MAPK signaling

    iScience

More on Triacylglyceride accumulation

Drug sensitivity

upin human cells1

1 study
  1. Trametinib increases drug sensitivity in human cells (Cluster 3 PDAC).

    “Drug screens revealed Cluster 3 as uniquely sensitive to Metformin and Trametinib, suggesting combinatory therapy potential.”

    CellsCluster 3 PDAC

    Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine

    BMC cancer

De novo lipogenesis enzyme abundance

downin mice1

1 study
  1. Trametinib decreases de novo lipogenesis enzyme abundance in mice.

    “The same pattern of changes in the de novo lipogenesis enzymes can be produced, in cultured cells or in intact mice, by trametinib”

    Animals

    The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

    Frontiers in aging

More on De novo lipogenesis enzyme abundance

Senescence-associated secretory phenotype (SASP)

downin human cells1

1 study
  1. Trametinib inhibits senescence-associated secretory phenotype (SASP) in DKFZ-BT66 cells.

    “Trametinib treatment inhibited MAPK activity, OIS and SASP signatures across all omics levels, functionally underscored by reduced sensitivity towards senolytic drugs.”

    Cellsin DKFZ-BT66 cells

    Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

    Signal transduction and targeted therapy

More on Senescence-associated secretory phenotype (SASP)

MAPK/ERK signaling

downin human cells1

1 study
  1. Trametinib inhibits MAPK/ERK signaling in DKFZ-BT66 cells.

    “Trametinib treatment inhibited MAPK activity, OIS and SASP signatures across all omics levels, functionally underscored by reduced sensitivity towards senolytic drugs.”

    Cellsin DKFZ-BT66 cells

    Multi-omics dissection of MAPK-driven senescence unveils therapeutic vulnerabilities in KIAA1549::BRAF-fusion pediatric low-grade glioma models

    Signal transduction and targeted therapy

More on MAPK/ERK signaling

CellPopAge clock age

downin human cells1

1 study
  1. Trametinib decreases CellPopAge clock age in human cells (passage-based culture of primary cells).

    “the CellPopAge Clock can detect decelerated passage-based ageing of human primary cells treated with rapamycin or trametinib”

    Cellspassage-based culture of primary cells

    An expedited screening platform for the discovery of anti-ageing compounds in vitro and in vivo

    Genome medicine

More on CellPopAge clock age

All 18

Has trametinib been tested in people?

0 of 207 about aging

207 trials are registered, but no study of it in people has been published yet.

Approved

  • EMA Mekinist

    Jun 30, 2014Melanoma, Lung Cancer, Non-Small Cell, differentiated thyroid cancer, Metastatic Melanoma, advanced non small cell lung cancer, Unresectable or Metastatic Melanoma

  • FDA Mekinist

    Mar 16, 2023Melanoma, Anaplastic Thyroid Cancer, Solid Tumors, Lung Cancer, Non-Small Cell, Metastatic Melanoma, Low Grade Glioma, metastatic non small cell lung cancer, Unresectable or Metastatic Melanoma

  • EMA Spexotras

    Jan 5, 2024Glioma, Low Grade Glioma, Glioma, High Grade

Repurposing

40 of 77

In trials

  • Neurofibromatosis 1

    Phase 4Active, not recruiting5 trials

  • Plexiform neurofibroma

    Phase 4Active, not recruiting4 trials

  • Ganglioneuroma

    Phase 4Active, not recruiting2 trials

  • Neurocytoma

    Phase 4Active, not recruiting2 trials

  • Neoplasm by histologic type

    Phase 2/3Recruiting2 trials

  • Neoplasm by site

    Phase 2/3Recruiting2 trials

All 30

Stopped

  • NCT01978236TerminatedBrain tumor

    This study was terminated due to the limited enrollment.

  • NCT02974803TerminatedBrain tumor

    Very slow accrual

  • NCT05518110TerminatedPancreatic neoplasms

    Study terminated due to futility

  • NCT04566133TerminatedCholangiocarcinoma

    Slow accrual

  • NCT01907815TerminatedLeukemia myeloid acute

    Lack of efficacy.

  • NCT01958112TerminatedUterine cervical neoplasm

    Drug supply

All 10

Who is developing trametinib?

3 companies: Novartis Pharmaceuticals, Genfit and Bristol-Myers Squibb.

Companies
  • Novartis PharmaceuticalsPhase 4melanoma, non-small cell lung cancer
  • GenfitPhase 1/2cholangiocarcinoma
  • Bristol-Myers SquibbPhase 1/2colorectal cancer, colorectal tumors

Trial sponsors

Funding

1 grant since 2022

Biotechnology and Biological Sciences Research Council£533K

Contains public sector information licensed under the Open Government Licence v3.0.

Latest

Dec 2025: 1Jan 2026: 2Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 2Nov 2026: 07 papers in 12 months
Neuro-oncology

Drug combination limited brain tumor regrowth in mice

In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.In mice carrying childhood brain tumor models, trametinib plus navitoclax reduced regrowth after treatment stopped and improved survival.

Mouse studyInterventions

See all 27 papers on trametinib